Effect of Admission Time on the Outcomes of Liver Cirrhosis with Acute Upper Gastrointestinal Bleeding: Regular Hours versus Off-Hours Admission

Table 3

Characteristics of patients with liver cirrhosis and AUGIB in validation cohort.

Variables	No. Pts	Overall	No. Pts	Regular hours	No. Pts	Off-hours	P value
Age (years)	173	56.60 (20.57-88.73)	131	56.60 (20.57-75.73)	42	56.56 (33.42-88.73)	0.683
Sex (male)	173	121 (69.9%)	131	91 (69.5%)	42	30 (71.4%)	0.809
Etiology of Liver Diseases	173		131		42		0.830
HBV		47 (27.2%)		37 (28.2%)		10 (23.8%)
HCV		17 (9.8%)		12 (9.2%)		5 (11.9%)
Alcohol Abuse		55 (31.8%)		41 (31.3%)		14 (33.3%)
HBV + Alcohol Abuse		3 (1.7%)		2 (1.5%)		1 (2.4%)
HBV + HCV + Alcohol Abuse		1 (0.6%)		1 (0.8%)		0 (0%)
Drug Related		1 (0.6%)		1 (0.8%)		0 (0%)
Autoimmune Liver Diseases		3 (1.7%)		3 (2.3%)		0 (0%)
Other or Unclear Etiology		46 (26.6%)		34 (25.9%)		12 (28.6%)
Laboratory Tests
Red Blood Cell (10^12/L)	173	2.70 (1.32-5.11)	131	2.70 (1.32-5.11)	42	2.62 (1.56-4.14)	0.372
Hemoglobin (g/L)	173	73.00 (31.00-156.00)	131	73.00 (31.00-156.00)	42	73.50 (38.00-130.00)	0.575
White Blood Cell (10^9/L)	173	4.20 (1.00-23.10)	131	4.10 (1.00-23.10)	42	4.35 (1.70-14.90)	0.368
Platelet Count (10^9/L)	173	71.00 (18.00-457.00)	131	73.00 (18.00-377.00)	42	68.50 (23.00-457.00)	0.980
Total Bilirubin (umol/L)	172	20.80 (5.20-210.00)	131	21.60 (5.20-210.00)	41	18.30 (6.70-106.10)	0.587
Direct Bilirubin (umol/L)	172	8.70 (2.00-146.90)	131	9.00 (2.00-146.90)	41	8.30 (2.50-60.10)	0.643
Indirect Bilirubin (umol/L)	172	10.65 (2.60-79.90)	131	11.40 (2.60-69.20)	41	9.80 (4.20-79.90)	0.801
Albumin (g/L)	171	29.40 (17.00-50.70)	130	29.65 (17.20-50.70)	41	29.40 (17.00-41.00)	0.693
Alanine Aminotransferase (U/L)	172	20.70 (5.00-275.36)	131	20.98 (6.00-140.00)	41	17.17 (5.00-275.36)	0.504
Aspartate Aminotransferase (U/L)	172	27.00 (9.63-310.39)	131	27.50 (9.63-278.00)	41	26.11 (10.00-310.39)	0.801
Alkaline Phosphatase (U/L)	172	78.23 (24.02-378.66)	131	75.66 (24.02-378.66)	41	79.75 (46.24-197.00)	0.981
Gamma-glutamyl Transpeptidase (U/L)	172	31.98 (7.54-1227.00)	131	29.61 (7.54-1227.00)	41	40.53 (7.69-295.00)	0.346
Blood Urea Nitrogen (mmol/L)	172	7.60 (2.17-47.25)	131	7.40 (2.17-47.25)	41	7.96 (2.47-20.15)	0.993
Serum Creatinine (umol/L)	172	69.145 (34.40-267.63)	131	67.03 (34.40-267.63)	41	74.21 (34.90-144.98)	0.116
Potassium (mmol/L)	173	3.95 (2.48-5.54)	131	3.95 (2.48-5.54)	42	3.97 (3.12-5.49)	0.876
Sodium (mmol/L)	173	138.50 (124.00-152.90)	131	138.40 (130.40-152.90)	42	138.80 (124.00-145.70)	0.544
PT (seconds)	171	16.10 (10.50-27.40)	131	16.10 (11.60-27.40)	40	16.05 (10.50-27.20)	0.606
APTT (seconds)	170	37.85 (19.40-59.70)	131	37.90 (27.50-59.70)	39	37.40 (19.40-52.10)	0.542
INR	170	1.32 (0.91-2.55)	131	1.33 (1.01-2.55)	39	1.31 (0.91-2.50)	0.681
Child-Pugh Score	169	8.00 (5.00-15.00)	130	8.00 (5.00-12.00)	39	7.00 (5.00-12.00)	0.603
Child-Pugh A/B/C	169	51 (30.2%)/94 (55.6%); /24 (14.2%)	130	37 (28.5%)/75 (57.7%); /18 (13.8%)	39	14 (35.9%)/19 (48.7%); /6 (15.4%)	0.596
MELD Score	170	7.22 (-3.16-23.19)	131	7.26 (-3.16-20.70)	39	7.22 (-2.38-23.19)	0.671
Recalibrated MELD Score	170	-3.82 (-5.97- -0.51)	131	-3.81 (-5.97- -1.03)	39	-3.82 (-5.80- -0.51)	0.671
ALBI Score	171	-1.63 (-3.40- -0.11)	130	-1.62 (-3.40- -0.11)	41	-1.68 (-2.70- -0.49)	0.675
Esophageal Varices (No/Mild/Moderate/Severe)	151	9 (6.0%)/23 (15.2%)/26 (17.2%)/93 (61.6%)	116	6 (5.2%)/18 (15.5%)/20 (17.2)/72 (61.1%)	35	3 (8.6%)/5 (14.3%)/6; (17.1%)/21 (60.0%)	0.965
Treatment
Endoscopic Treatment	173	139 (80.3%)	131	104 (79.4%)	42	35 (83.3%)	0.576
Sengstaken Blakemore	173	1 (0.6%)	131	0 (0%)	42	1 (2.4%)	0.077
Somatostatin and/or Octreotide	173	160 (92.5%)	131	119 (90.8%)	42	41 (97.6%)	0.147
Blood Transfusion	173	88 (50.9%)	131	62 (47.3%)	42	26 (61.9%)	0.100
PPIs	173	173 (100%)	131	131 (100%)	42	42 (100%)	NA
Surgery	173	0 (0%)	131	0 (0%)	42	0 (0%)	NA
5-day Re-bleeding After Treatment	172	13 (7.6%)	130	9 (6.9%)	42	4 (9.5%)	0.579
Death During Hospitalization	173	4 (2.3%)	131	3 (2.3%)	42	1 (2.4%)	0.973
Length of Stay (days)	173	10.10 (0.12-32.94)	131	10.10 (0.12-32.94)	42	10.28 (5.02-31.06)	0.335
Total Payment (¥)	173	24,328.31 (3,427.24-98,215.78)	131	22,685.20 (3,427.24-98,215.78)	42	25,213.81 (9,970.37-81,125.52)	0.166

Data are expressed as median (range) or frequency (percentage).
Abbreviations. AUGIB: acute upper gastrointestinal bleeding; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; MELD: model for end-stage liver disease; ALBI: albumin-bilirubin; PPIs: proton pump inhibitors; ¥: Renminbi.